Center-Authored Papers

Filters: Author is Furlong, Terry  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Carnevale-Schianca F, Leisenring WM, Martin PJ, Furlong T, Schoch G, Anasetti C, Appelbaum FR, Carpenter PA, Deeg HJ, Kiem H-P et al..  2009.  Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(6):749-56. Abstract
F
Furlong T, Kiem H-P, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K, Flowers MED, Mielcarek M, Nash RA, Storb R et al..  2008.  Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(5):531-7. Abstract
I
Inamoto Y, Flowers MED, Appelbaum FR, Carpenter PA, Deeg HJ, Furlong T, Kiem H-P, Mielcarek M, Nash RA, Storb R et al..  2011.  A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(7):1088-92. Abstract
K
Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF et al..  2014.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(31):3497-505. Abstract
Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith DB et al..  2017.  Low immunosuppressive burden after HLA-matched related or unrelated BMT using post-transplantation cyclophosphamide.. Blood. Abstract
M
Martin PJ, Furlong T, Rowley SD, Pergam SA, Lloid M, Schubert MM, Horgan KJ, Storer BE.  2012.  Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(6):922-929. Abstract
McCune JS, Woodahl EL, Furlong T, Storer BE, Wang J, Heimfeld S, Deeg HJ, O'Donnell PV.  2012.  A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.. Cancer chemotherapy and pharmacology. 69(1):263-272. Abstract
Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers MED, Appelbaum FR, Martin PJ.  2016.  Post-transplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.. Blood. Abstract
Mielcarek M, Storer BE, Boeckh MJ, Carpenter PA, McDonald GB, Deeg HJ, Nash RA, Flowers MED, Doney K, Lee SJ et al..  2009.  Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.. Blood. 113(13):2888-94. Abstract
S
Steinbach G, Hockenbery DM, Huls G, Furlong T, Myerson D, Loeb KR, Fann JR, Castilla-Llorente C, McDonald GB, Martin PJ.  2017.  Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease.. PloS one. 12(8):e0183284. Abstract